Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Triple-Negative Breast Carcinoma”

71 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 71 results

Testing effectiveness (Phase 2)UnknownNCT05340413
What this trial is testing

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
SOLTI Breast Cancer Research Group 63
Early research (Phase 1)WithdrawnNCT06590558
What this trial is testing

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Large-scale testing (Phase 3)Active Not RecruitingNCT05347134
What this trial is testing

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 254
Early research (Phase 1)Ended earlyNCT02419495
What this trial is testing

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+26 more
M.D. Anderson Cancer Center 221
Testing effectiveness (Phase 2)Active Not RecruitingNCT02498613
What this trial is testing

Cediranib in Combination With Olaparib in Advanced Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell Carcinoma+23 more
National Cancer Institute (NCI) 122
Testing effectiveness (Phase 2)Ended earlyNCT03184558
What this trial is testing

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Who this might be right for
Triple Negative Breast CancerInflammatory Breast Cancer Stage IV
BerGenBio ASA 29
Testing effectiveness (Phase 2)Study completedNCT04464174
What this trial is testing

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
MedSIR 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383196
What this trial is testing

Onvansertib + Paclitaxel In TNBC

Who this might be right for
Breast CancerInvasive Breast CancerUnresectable Breast Carcinoma+7 more
Antonio Giordano, MD 50
Early research (Phase 1)Looking for participantsNCT05107674
What this trial is testing

NX-1607 in Adults With Advanced Malignancies

Who this might be right for
Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more
Nurix Therapeutics, Inc. 345
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07040644
What this trial is testing

Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Who this might be right for
Triple Negative Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 150
Early research (Phase 1)Active Not RecruitingNCT02432963
What this trial is testing

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Who this might be right for
Adult Solid NeoplasmBladder CarcinomaColon Carcinoma+14 more
City of Hope Medical Center 11
Early research (Phase 1)Study completedNCT00576654
What this trial is testing

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmTriple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI) 73
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Large-scale testing (Phase 3)Looking for participantsNCT06841354
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Who this might be right for
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT04345913
What this trial is testing

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI) 24
Large-scale testing (Phase 3)Looking for participantsNCT06279364
What this trial is testing

SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 524
Early research (Phase 1)Ended earlyNCT02706392
What this trial is testing

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Lung Non-Small Cell Carcinoma+10 more
Fred Hutchinson Cancer Center 21
Load More Results